Endonovo Therapeutics (ENDV) 10-Q18 Dec 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Dec. 15, 2013
Document And Entity Information	'	'
Entity Registrant Name	'Hanover Portfolio Acquisitions, Inc.	'
Entity Central Index Key	'0001528172	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'Yes	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	80,197,314
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets	'	'
Cash	$1,208	$800
Total Current Assets	1,208	800
Property Plant and Equipment, net	50,688	65,301
Investment in securities	12,000	12,000
Total Assets	63,896	78,101
Current Liabilities	'	'
Accounts payable and accrued expenses	2,833,523	1,516,600
Notes payable, net discount of $24,491 and $0	478,177	236,000
Note payable-related party, net of discount of $8 and $0	16,980	0
Total Current Liabilities	3,328,680	1,752,600
Notes payable	43,188	51,656
Acquisition payable	155,000	155,000
Total Liabilities	3,526,868	1,959,256
Shareholders' Deficit	'	'
Series AA super voting preferred stock, $0.0001 par value, 1,000,000 authorized and 0 issued and outstanding	0	0
Preferred stock, $0.0001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding	0	0
Common stock, $0.0001 par value; 250,000,000 shares authorized, 75,828,913 and 53,692,673 shares issued and outstanding	7,583	5,370
Additional paid-in capital	1,188,372	554,062
Accumulated deficit	-4,658,927	-2,440,587
Total Shareholders' Deficit	-3,462,972	-1,881,155
Total Liabilities and Shareholders' Deficit	$63,896	$78,101

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Series AA Preferred Stock	'	'
Series AA Preferred stock, par value	$0.00	$0.00
Series AA Preferred stock, authorized	1,000,000	1,000,000
Series AA Preferred stock, issued	0	0
Series AA Preferred stock, outstanding	0	0
Preferred Stock	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
COMMON STOCK	'	'
Common stock, par value	$0.00	$0.00
Common stock, authorized	250,000,000	250,000,000
Common stock, issued	75,828,913	53,692,673
Common stock, outstanding	75,828,913	53,692,673
Current notes payable discount	$24,491	$0
Current notes payable discount, related party	$8	$0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
Consolidated Statements of Operations (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
Revenues, net	$0	$7,161	$0	$16,926
Operating Expenses	427,819	379,801	1,934,752	1,210,768
Operating Loss	-427,819	-372,640	-1,934,752	-1,193,842
Other Income (Expense)	'	'	'	'
Impairment expense	0	0	-101,957	-155,000
Interest income	142	0	4,174	11
Interest expense	-24,720	-20,259	-185,273	-60,459
Loss Before Provision for Income Taxes	-452,397	-392,899	-2,217,808	-1,409,290
Provision for Income Taxes	0	0	532	0
Net Loss	($452,397)	($392,899)	($2,218,340)	($1,409,290)
Basic and diluted loss per common share	($0.01)	($0.01)	($0.03)	($0.03)
Weighted average common share outstanding - basic and diluted	73,059,691	51,150,496	66,938,685	46,681,067

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	9 Months Ended
Consolidated Statement of Cash Flows (USD $)	Sep. 30, 2013	Sep. 30, 2012
Cash Flows From Operating Activities	'	'
Net loss	($2,218,340)	($1,409,290)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Depreciation and amortization expense	14,369	36,891
Impairment expense	101,957	0
Fair value of equity issued for services	480,048	178,897
Acquisition expense	0	155,000
Amortization of note discount	-131,992	0
Changes in operating assets and liabilities:	'	'
Account receivable	0	2,918
Prepaid expenses	0	-14,000
Accounts payable and accrued expenses	1,286,223	820,387
Net Cash Used in Operating Activities	-203,751	-229,197
Cash Flows From Investing Activities	'	'
Purchase of property, plant and equipment	244	0
Net cash received in acquisition of subsidiary	3,743	53,048
Net Cash Provided by Investing Activities	3,987	53,048
Cash Flows From Financing Activities	'	'
Sale of common stock	0	170,000
Proceeds from the issuance of notes payable	185,000	0
Proceeds from the issuance of notes payable - related party	25,000	0
Payment for notes payable - related party	-8,012	0
Payment for notes payable	-1,816	0
Net Cash Provided by Financing Activities	200,172	170,000
Net Increase (Decrease) in Cash	408	-6,149
Cash, Beginning of Period	800	9,247
Cash, End of Period	1,208	3,098
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash financing and investing:	'	'
Debt acquired in acquisition	98,150	0
Debt acquired in purchase of property, plant and equipment	58,112	0
Acquisition payable	$155,000	$155,000

Note_1_Organization_and_Nature

Note 1 - Organization and Nature of Business	9 Months Ended
Note 1 - Organization and Nature of Business	Sep. 30, 2013
Notes to Financial Statements	'
Note 1 - Organization and Nature of Business	'
	Note 1 - Organization and Nature of Business

	Hanover Portfolio Acquisitions, Inc. and Subsidiaries (the “Company” or “HPA”) operates in two business segments: 1) purchases distressed debt portfolios at a significant discount to their face value and seeks to either collect on the outstanding balances or resell some or all of the portfolios and 2) intellectual property licensing and commercialization.

	Reverse Acquisition

	On March 14, 2012, HPA, entered into a Share Exchange Agreement (“Agreement”) with IP Resources International (“IPR”) and certain of its shareholders. Under the Agreement, each participating IPR shareholder exchanged all of their issued and outstanding IPR common shares totaling 33,234,294, free and clear of all liens, and $155,000 for Company common shares of equal to 1.2342 times the number of IPR shares being transferred to the Company for a total of 41,017,766 shares. The $155,000 was not paid at closing. The Company recorded the $155,000 as long-term liability acquisition payable, which is non-interest bearing. IPR agreed to make payments of up to 25% of the proceeds from any private placement or gross profits earned by IPR until the obligation is satisfied. The percentage of the proceeds to be paid is at the sole discretion of IPR’s Chief Executive Officer and the ex-Chief Executive Officer of the Company based on the liquidity of the Company.

	As a result of the Agreement, the former shareholders of IPR owned approximately 89% of the Company and its officer and directors constitute the majority of the officers and directors of the Company at the closing. Since the shareholders, officers and directors of IPR have control of the Company the acquisition constitutes a reverse acquisition, so IPR is the accounting acquirer and HPA is the accounting acquiree. For accounting purposes, IPR becomes the parent and HPA becomes a wholly owned subsidiary. In comparison, the legal form of the acquisition is that HPA is the legal parent and IPR is the legal subsidiary.

	The accompanying condensed consolidated financial statements are presented as IPR being the parent company and HPA as the wholly owned subsidiary with the historical financial position and results of operations being of the operations of IPR, which include the results of operations of HPA from the date of acquisition on March 14, 2012. IPR began its operations on September 1, 2011.

	As of the date of the acquisition, the sole director and officer and significant shareholder of HPA was a significant shareholder of IPR. Given the relationship, the transaction is considered not to be an arms length transaction and a step-up in the basis of the assets and liabilities acquired is precluded, as the transfer of assets and liabilities has not been affected. The Company has recorded the acquisition and issuance of 4,557,545 shares of its common stock at a value of $60,166, which is the historical cost basis of HPA as of the date of the transaction. As of the date of the acquisition, HPA balance sheet consisted of cash of $53,048, accounts receivable of $4,954, fixed assets of $2,164 and no liabilities, for a net book value of $60,166.

	The Aviva Companies Corporation Acquisition

	On April 2, 2013, the Company entered into an Acquisition Agreement (the “Acquisition Agreement”) with (i) The Aviva Companies Corporation (“Aviva”) and (ii) all of the shareholders of Aviva (the “Shareholders”) pursuant to which the Company acquired all of the outstanding shares of Aviva in exchange for the issuance of 6,000,000 shares of our common stock, par value $0.0001 per share to the Shareholders (the “Share Exchange”). As a result of the Share Exchange, Aviva became a wholly-owned subsidiary of the Company. The Company has not provided all the detailed disclosures for this transaction pursuant to ASC 805 as the transaction closed within a period of time that did not permit the Company to accurately assess and gather the required information.

	Aviva is an early stage company seeking to identify, and commercialize intellectual property in healthcare and technology. Aviva works closely with inventors of IP in both the United States and Israel.

	Basis of Presentation and Principles of Consolidation

	The accompanying unaudited interim condensed consolidated financial statements of Hanover Portfolio Acquisition’s, Inc. and Subsidiaries have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30,2013 and 2012 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The results of operations for the Period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

	The consolidated financial statements of the Company include the accounts of HPA, IPR as of March 14, 2013 and Aviva as of April 2, 2013. All significant intercompany accounts and transactions are eliminated in consolidated.

	Use of Estimates
	The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.

	Liquidity

	To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from it license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Although, uncertainty exists as to whether the Company will be able generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.

	Recent Accounting Standard Updates

	The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operations.

Note_2_Acquisition

Note 2 - Acquisition	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Note 2 - Acquisition	'
	Note 2 - Acquisition

	On April 2, 2013, the Company entered into an Acquisition Agreement (the “Acquisition Agreement”) with (i) The Aviva Companies Corporation (“Aviva”) and (ii) all of the shareholders of Aviva (the “Shareholders”) pursuant to which the Company acquired all of the outstanding shares of Aviva in exchange for the issuance of 6,000,000 shares of our common stock, par value $0.0001 per share to the Shareholders (the “Share Exchange”). As a result of the Share Exchange, Aviva became a wholly-owned subsidiary of the Company.

	Other than in respect to the transaction, there is no material relationship among Aviva’s stockholders and any of the Company’s affiliates, directors or officers.

	The following table summarizes the estimated fair values at the date of acquisition:

	Current assets	$ 4,043
	Goodwill	101,957
	Current liabilities	-100,000
	Total purchase consideration	$ 6,000


	The purchase consideration was comprised entirely of shares of Hanover Portfolio Acquisitions, Inc. and Subsidiaries issued to the former shareholders of Aviva Companies Corporation, which were valued at $6,000 on the date of acquisition.

	Hanover Portfolio Acquisitions, Inc. and Subsidiaries assumed the outstanding debts of The Aviva Company Corporations and all outstanding accrued interest. The principal balance of these notes acquired on April 2, 2013 was $75,000 with accrued interest of $21,275, see note 4.

	Goodwill

	The Company reviews the amounts of intangible assets for impairment at least annually, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In the event the carrying value of the assets is not expected to be recovered, the assets are written down to their estimated fair values.

	During the period ended September 30, 2013, the intangible assets acquired in the acquisition were reviewed and the Company determined them to be fully impaired, as such the Company recorded an impairment expense of $101,957.


	Goodwill as of December 31, 2012	$ -
	Goodwill acquired on April 2, 2013	101,957
	Impairment of Goodwill	-101,957
	Net Goodwill as of September 30, 2013	$ -

Note_3_Intangible_Assets

Note 3 - Intangible Assets	9 Months Ended
Note 3 - Intangible Assets	Sep. 30, 2013
Notes to Financial Statements	'
Note 3 - Intangible Assets	'
	Note 3 - Intangible Assets

	Personal 3D

	Effective September 1, 2011, IPR entered into a license agreement with Personal 3D, Inc. (“P3D”) to acquire the rights to market and distribute certain intellectual property in the territories of the European and Eastern European countries. The term of the license agreement was to be for the greater of the life of the provisional patents, for the technology, or twenty-one years. The term was to automatically renew for an additional one year term unless either party notified the other that it does not desire to renew the license agreement ninety days before the then-current term of the license agreement expires. The license fee to be paid by IPR was $1,000,000 and common stock of IPR in an amount that would give P3D 9.9% interest in outstanding common stock of IPR (“Share Issuance”). The Shares Issuance was to be issued on or before October 12, 2011, (actually issued on October 17, 2011 the date of incorporation of IPR). The Company paid $10,000 towards the promissory note on October 18, 2011.

	The unpaid balance of the note bore simple interest at a rate of 6% per annum commencing on the date of the initial payment of $10,000.

	On October 14, 2012, the Company and P3D entered into an agreement to terminate the license agreement. Under the terms of the termination, P3D was required to surrender the Share Issuance and the IPR was released of its liability under the Note Payable – License Fee, which amounted to $990,000 on the date of termination. The Company recognized a gain of $96,347 as a result of the termination of this agreement.

	The Company’s CEO was also the CEO of P3D at the time the license agreement was executed; however he resigned from P3D prior to the execution of the license rescission agreement.

	CPAIR, Inc.

	Effective November 11, 2011, IPR entered into an Exclusive License Agreement with CPAIR, Inc. (“CPaiR”) to acquire the rights to market and distribute certain intellectual property on a worldwide basis except for the United States. The terms of the license agreement shall be for the greater of the life of the provisional patents, for the technology, or twenty-one years. The term shall automatically renew for an additional one year term unless either party notifies the other that it does not desire to renew the license agreement ninety days before the then-current term of the license agreement expires. Under the Exclusive License Agreement, if IPR enters into a sublicense agreement, IPR is required to pay CPaiR 20% of royalties received by IPR. If IPR elects to distribute the product, without sublicenses, then CPaiR receives 10% of gross revenues. Also, IPR is required to pay to CPaiR 20% of any upfront license fee actually received by IPR in connection with the CPaiR intellectual property and 20% of the quarterly revenue actually received by IPR in connection with such intellectual property. If IPR does not pay a minimum of $1,000,000 to CPaiR within a period of three years from the Effective date, the license agreement will terminate. IPR has the right to pay the difference between the amounts paid by IPR and the minimum payment of $1,000,000. Under the terms of the agreement, IPR was not required to pay an upfront license fee.

	American Cryostem Corp.

	Effective January 27, 2012, IPR entered into a License Agreement with American Cryostem Corp. ("ACSC") to acquire the rights to and to distribute certain intellectual property in China and Brazil. The term of the License Agreement shall be for one year. The term shall automatically renew for an additional one-year term unless either party notifies the other that it does not desire to renew the License Agreement. Under the License Agreement, any distributer or sub-licensee, engaged by IPR, must pay 25% of its quarterly gross revenue. Of the 25% of quarterly gross revenue, IPR and ACSC split 50/50. In the event that IPR receives any upfront license fee from a sub-licensee, IPR is required to pay to ACSC 50% of any upfront license fee actually received. Under the terms of the agreement, IPR was not required to pay an upfront license fee.

	Aviva Companies Corporation Acquisition

	In connection with the acquisition of Aviva Companies Corporation on April 2, 2013, the Company acquired goodwill of $101,957. The Company assessed the fair value of the Goodwill acquired in the acquisition and determined the asset to be fully impaired and recorded impairment expense of $101,957 as of September 30,2013, see note 2.

Note_4_Notes_payable

Note 4 - Notes payable	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
Note 4 - Notes payable	'
	Note 4 - Notes payable

	In 2012, IPR initiated a private placement for up to $1,000,000 of financing by the issuance of notes payable at a minimum of $25,000. The notes bear interest at 12% per annum and are due and payable with accrued interest one year from issuance. Also, IPR agreed to issue 102,850 shares of its common stock for every $25,000 invested.

	Under the private placement, the Company has issued a total of two notes for an aggregate principal amount of $175,000. In addition IPR issued 719,950 share of its common stock at a fair value of $3,917 as determined using a valuation performed by a third party valuation firm. In October 2012, the two note holders agreed to extend the maturity date of the notes for a period of one year. The Company paid an extension of 175,000 shares of the Company’s common stock at a fair value of $175 as determined by a valuation performed by a third party valuation firm. As of September 30, 2013, the balance outstanding on these notes is $175,000.

	In October and November 2012, the Company issued two (2) promissory notes in the amounts of $25,000 and $25,000, respectively. In addition the Company issued 250,000 share of its common stock at a fair value of $250 as determined by a valuation performed by a third party valuation firm. As of September 30, 2013, the balances of these notes were $25,000 and $25,000, respectively.

	These notes payable, which aggregate $225,000 as of September 30, 2013, mature as follows: $150,000 in September 2013, $50,000 in October 2013 and $25,000 in January 2013. The note which matured in January 2013 remains outstanding as of September 30, 2013.

	In November 2012, the Company purchased a vehicle for $64,458. The purchase was financed through a note payable for $64,458 at interest of 2.99% per annum with sixty payments of $1,060 per month. As of September 30, 2013 the balance of the note was $60,840.

	On January 14, 2013, the Company issued a promissory note for an aggregate principal amount of $25,000. In addition, the Company issued 125,000 shares of its common stock in connection with the issuance of the note as loan fees. These shares were valued at their issuance date fair market value and $25,000 was recorded as a note discount with the excess $12,500 recognized as a charge to interest expense upon issuance. The note carries an interest rate of 10% per annum and a maturity date of April 14, 2013 with interest due monthly in arrears. As of September 30, 2013, the outstanding balance on the note was $25,000 and no interest has been paid to date.

	On January 14, 2013, the Company issued a promissory note for an aggregate principal amount of $25,000. In addition, the Company issued 125,000 shares of its common stock in connection with the issuance of the note as loan fees. These shares were valued at their issuance date fair market value and $25,000 was recorded as a note discount with the excess $12,500 recognized as a charge to interest expense upon issuance. The note carries an interest rate of 10% per annum and a maturity date of July 1, 2013 with interest due monthly in arrears. As of September 30, 2013, the balance of the note was $25,000 and no interest has been paid to date.

	On January 31, 2013, the Company issued a promissory note for an aggregate principal amount of $100,000. In addition, the Company issued 500,000 shares of its common stock in connection with the issuance of the note as loan fees. These shares were valued at their issuance date fair market value of $75,000, which was recorded as a note discount. The note carries an interest rate of 10% per annum and a maturity date of January 30, 2014 with interest due monthly in arrears. As of September 30, 2013 the outstanding balance of the note was $100,000 and no interest has been paid to date.

	In connection with acquisition of Aviva Companies Corporation on April 2, 2013, the Company assumed a note payable for an aggregate principal amount of $25,000 and accrued interest of $1,042 as of April 2, 2013. The note accrues interest of 10% per annum and matured on May 1, 2013 however remains outstanding as of September 30, 2013 accruing interest. As of September 30, 2013 the outstanding balance of the note was $25,000.

	In connection with acquisition of Aviva Companies Corporation on April 2, 2013, the Company acquired a note payable for an aggregate principal amount of $50,000 and accrued interest of $20,233 as of April 2, 2013. The note accrued interest of 10% per annum and matured on May 1, 2013, however remains outstanding as of September 30, 2013 accruing interest. As of September 30, 2013 the outstanding balance on the note was $50,000.

	On August 30, 2013, the Company issued a promissory note for an aggregate principal amount of $25,000. In addition, the Company issued 125,000 shares of its common stock in connection with the issuance of the note as loan fees. These shares were valued at their issuance date fair market value of $125, which was recorded as a note discount. The note carries an interest rate of 10% per annum, however, during the continuance of any event of default, the Interest rate shall be increased to fourteen (14%) percent per annum. The interest shall be payable in arrears on the maturity date.. The maturity date of the note is the earlier of July 1, 2014 or the closing of a “Qualified Financing”, an equity financing for gross proceeds of not less than $5,000,000. As of September 30, 2013 the outstanding balance of the note was $25,000.

	On September 25, 2013, the Company issued a promissory note for an aggregate principal amount of $10,000. In addition, the Company issued 50,000 shares of its common stock in connection with the issuance of the note as loan fees. These shares were valued at their issuance date fair market value of $50, which was recorded as a note discount. The note carries an interest rate of 10% per annum, however, during the continuance of any event of default, the Interest rate shall be increased to fourteen (14%) percent per annum. The interest shall be payable in arrears on the maturity date.. The maturity date of the note is the earlier of July 1, 2014 or the closing of a “Qualified Financing”, an equity financing for gross proceeds of not less than $5,000,000. As of September 30, 2013 the outstanding balance of the note was $10,000.

	Promissory Note - Related Party

	On May 10, 2013, the Company issued a promissory note to an affiliate for an aggregate principal amount of $25,000. In addition, the Company issued 125,000 shares of its common stock in connection with the issuance of the note as loan fees. The Note carries an interest rate of 8% per annum and a maturity date of October 10, 2013 with interest due in arrears. A note discount of $125 was recorded on date of issuance. As of September 30, 2013 the outstanding balance on the note was $16,988.

	Amortization of note discounts amounted to $103,566 during the period ended September 30, 2013. As of September 30, 2013, there was $24,491 of note discount unamortized.

	As of September 30, 2013, future minimum payments due fiscal years due on notes payable are as follows:

	Fiscal Year
	2014	$524,000
	2015	12,000
	2016	12,000
	2016	12,000
	2018	158,000
		$718,000

Note_5_Shareholders_Deficit

Note 5 - Shareholders' Deficit	9 Months Ended
Note 5 - Shareholders' Deficit	Sep. 30, 2013
Notes to Financial Statements	'
Note 5 - Shareholders' Deficit	'
	Note 5- Shareholders’ Deficit

	Common Stock

	The Company has entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulate a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant is issued a prorated number of shares of common stock at the beginning of the contract, which the consultant earns over a three-month period. At the anniversary of each quarter, the consultant is issued a new allotment of common stock. In accordance with ASC 505-50 – Equity-Based Payment to Non-Employees, the common stock shares issued to the consultant are valued upon their vesting, with interim estimates of value as appropriate during the vesting period. The shares of common stock that have vested through January 2013 were valued based on a valuation performed by an independent valuation firm as the Company had no active market for its shares prior to that time. The Company’s shares began trading in January 2013; as a result the Company utilized market value for its stock when valuing its common stock for the three months ended March 31, 2013. During the second quarter of 2013, the Company revalued the shares based on low trading volume to $0.001. As of September 30, 2013, the total awards granted were 47,412,620_ shares with 27,657,197 shares vested and issued and 19,755,423 shares unvested. The total expense recorded for the Nine Months Ended September 30, 2013 and 2012, was $479,639 and $178,897, respectively. On June 18, 2013, Hanover Portfolio Acquisitions, Inc. (the "Company") received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding shares of voting stock of the Company approving an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of the Company's Common Stock, from 75,000,000 shares to 250,000,000 shares. The increase in authorized shares was effected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on September 20, 2013, and a Certificate of Correction to the of Certificate of Amendment (the “Certificate of Correction”, together with the Certificate of Amendment, the “Certificates”), filed with the Secretary of State of the State of Delaware on September 26, 2013 to correctly state the par value of the Company’s Common Stock as $0.0001 per share. Definitive confirmation of the filing of the Certificates was received on October 10, 2013.

	Series AA Preferred Shares

	On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof.

	Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. As of September 30, 2013, there were no shares of Series AA Preferred stock outstanding.

Note_6_Segment_Information

Note 6 - Segment Information	9 Months Ended
Note 6 - Segment Information	Sep. 30, 2013
Notes to Financial Statements	'
Note 6 - Segment Information	'
	Note 6 - Segment Information

	The Company has two reporting segments: debt portfolio management and intellectual property management. The debt portfolio segment purchases defaulted unsecured consumer receivables in the secondary market and generate revenue through collections utilizing an outsourced collection network and through the strategic resale of portfolios. The intellectual property management segment licenses various commercially desirable technologies and patents from companies that need operating capital or that need help commercializing their technology and sublicense such technology in designated territories. We have no intersegment sales or transfer. The Company’s reportable segments are strategic business units that offer different products and services. They are managed separately because each business requires different technology and marketing strategies. Most of the businesses were acquired as a unit, and the management at the time of the acquisition was retained.

	Through September 30, 2013, all of the Company’s revenue has been generated from our debt portfolio segment.

	For the three and Nine Months Ended September 30, 2013, net revenues of $0 were contributed from our debt portfolio segment. For the three months ended September 30, 2013, the Company’s operating loss of approximately $428,000 was contributed by the intellectual property management for approximately $327,000 and the debt portfolio management for approximately $101,000, respectively. For the Nine Months Ended September 30, 2013, the Company’s operating loss of approximately $1,935,000 was contributed by the intellectual property management for approximately $1,639,000 and the debt portfolio management for approximately $296,000 respectively.

	For the three and Nine Months Ended September 30, 2012, net revenues of $7,161 and $16,926, respectively are contributed from our debt portfolio segment. For the three months ended September 30, 2012, the Company’s operating loss of approximately $393,000 was contributed by the intellectual property management for approximately $324,000, the debt portfolio management for approximately $25,000 and corporate overhead for approximately $44,000, respectively. For the Nine Months Ended September 30, 2012, the Company’s operating loss of approximately $1,409,000 was contributed by the intellectual property management for approximately $1,076,000, the debt portfolio management for approximately $79,000 and corporate overhead for approximately $254,000, respectively.

Note_7_Fair_Value_Measurements

Note 7 - Fair Value Measurements	9 Months Ended
Note 7 - Fair Value Measurements	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Note 7 - Fair Value Measurements	'
	Note 7 - Fair Value Measurements

	The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows:

	Level 1 – Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities.

	Level 2 – Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly.

	Level 3 – Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management’s best estimate of what market participants would use in valuing the asset or liability at the measurement date.

	The following table summarizes fair value measurements at September 30, 2013 and December 31, 2012 for assets and liabilities measured at fair value on a recurring basis:

	30-Sep-13
		Level 1	Level 2	Level 3	Total
	Cash and Cash Equivalents	$1,208	$ -	$ -	$1,208

	31-Dec-12
		Level 1	Level 2	Level 3	Total
	Cash and Cash Equivalents	$800	$ -	$ -	$800

Note_8_Subsequent_Events

Note 8 - Subsequent Events	9 Months Ended
Note 8 - Subsequent Events	Sep. 30, 2013
Subsequent Events [Abstract]	'
Note 8 - Subsequent Events	'
	Note 8 - Subsequent Events

	November 16, 2013, the Company entered into an Acquisition Agreement (the “Acquisition Agreement”) with (i) WeHealAnimals, Inc. (“WHA”) and (ii) the sole shareholder of WHA (the “Shareholders”) pursuant to which the Company acquired all of the outstanding shares of WHA in exchange for the issuance of 300,000 shares of our common stock, par value $0.0001 per share and a promissory note for $96,000 to the Shareholder (the “Exchange”). As a result of the Exchange, WHA became a wholly-owned subsidiary of the Company. The Company has not provided all the detailed disclosures for this transaction pursuant to ASC 805 as the transaction closed within a period of time that did not permit the Company to accurately assess and gather the required information.

	On October 1, 2013, the Company issued Alan Collier 1,000 shares of Series AA Super Voting Preferred Stock.

Note_1_Organization_and_Signif

Note 1 - Organization and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Notes to Financial Statements	'
Basis of Presentation and Principles of Consolidation	'
	Basis of Presentation and Principles of Consolidation

	The accompanying unaudited interim condensed consolidated financial statements of Hanover Portfolio Acquisition’s, Inc. and Subsidiaries have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of September 30,2013 and 2012 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The results of operations for the Period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

	The consolidated financial statements of the Company include the accounts of HPA, IPR as of March 14, 2013 and Aviva as of April 2, 2013. All significant intercompany accounts and transactions are eliminated in consolidated.

Use of Estimates	'
	Use of Estimates
	The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.

Liquidity	'
	Liquidity

	To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from it license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Although, uncertainty exists as to whether the Company will be able generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.

Recent Accounting Standard Updates	'
	Recent Accounting Standard Updates

	The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operations.

Note_7_Fair_Value_Measurements1

Note 7 - Fair Value Measurements (Policies)	9 Months Ended
Note 7 - Fair Value Measurements (Policies)	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements

	The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows:

	Level 1 – Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities.

	Level 2 – Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly.

	Level 3 – Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management’s best estimate of what market participants would use in valuing the asset or liability at the measurement date.

Note_2_Acquisition_Tables

Note 2 - Acquisition (Tables)	9 Months Ended
Note 2 - Acquisition (Tables)	Sep. 30, 2013
Business Combinations [Abstract]	'
Estimated fair values of acquisition	'
	Current assets	$ 4,043
	Goodwill	101,957
	Current liabilities	-100,000
	Total purchase consideration	$ 6,000
Goodwill	'
	Goodwill as of December 31, 2012	$ -
	Goodwill acquired on April 2, 2013	101,957
	Impairment of Goodwill	-101,957
	Net Goodwill as of June 30, 2013	$ -

Note_4_Notes_payable_Tables

Note 4 - Notes payable (Tables)	9 Months Ended
Note 4 - Notes payable (Tables)	Sep. 30, 2013
Notes to Financial Statements	'
Future minimum payments	'
	Fiscal Year
	2013	$481,362
	2014	12,720
	2015	12,720
	2016	12,720
	2017	12,720
	Thereafter	158,598
		$690,840

Note_7_Fair_Value_Measurements2

Note 7 - Fair Value Measurements (Tables)	9 Months Ended
Note 7 - Fair Value Measurements (Tables)	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	30-Sep-13
		Level 1	Level 2	Level 3	Total
	Cash and Cash Equivalents	$1,208	$ -	$ -	$1,208

	31-Dec-12
		Level 1	Level 2	Level 3	Total
	Cash and Cash Equivalents	$800	$ -	$ -	$800

Note_1_Organization_and_Signif1

Note 1 - Organization and Significant Accounting Policies (Details Narrative) (USD $)	1 Months Ended
	Nov. 30, 2012	Oct. 31, 2012	Sep. 30, 2013	Apr. 02, 2013	Dec. 31, 2012	Mar. 14, 2012
Reverse Acquisition	'	'	'	'	'	'
IPR common shares transferred for HPA common shares per Share Exchange Agreement	'	'	'	'	'	33,234,294
Cash payment pleged by IPR per Share Exchange Agreement	'	'	'	'	'	$155,000
Share exchange ratio	'	'	'	'	'	1.2342
Shares of HPA issued for IPR shares	'	'	'	'	'	41,017,766
Payment due recorded as long-term liability acquisition payable	'	'	'	'	'	155,000
Maximum percent of IPR proceeds from any private placement or gross profits earned by IPR agreed to be paid to HPA until the obligation is satisfied	'	'	'	'	'	25.00%
Percent of shares owned by former shareholders of IPR	'	'	'	'	'	89.00%
Shares issued in acquisition	'	'	'	'	'	4,557,545
Value of shares issued in acquisition	'	'	'	'	'	60,166
Cash	'	'	1,208	'	800	53,048
Accounts receivable	'	'	'	'	'	4,954
Fixed assets	'	'	63,896	'	78,101	2,164
Liabilities	'	'	3,526,868	'	1,959,256	0
Net book value of HPA	'	'	'	'	'	60,166
Common stock issued to Aviva for all of their outstanding shares, shares	'	'	'	6,000,000	'	'
Common stock issued to Aviva for all of their outstanding shares, value	'	'	'	6,000	'	'
Debt financing raised	$25,000	$25,000	'	'	'	'

Note_2_Acquisition_Details

Note 2 - Acquisition (Details) (USD $)	9 Months Ended
Note 2 - Acquisition (Details) (USD $)	Sep. 30, 2013	Apr. 02, 2013	Dec. 31, 2012
Estimated fair value of acquisition of Aviva	'	'	'
Current Assets of Aviva	'	$4,043	'
Goodwill of Aviva	'	101,957	'
Current liabilities of Aviva	'	-100,000	'
Total purchase consideration of Aviva	'	6,000	'
Goodwill acquired in acquisition of Aviva	'	'	'
Goodwill	'	'	0
Goodwill Acquired	'	101,957	'
Impairment of Goodwill	-101,957	'	'
Net Goodwill	$0	'	'

Note_2_Acquisition_Details_Nar

Note 2 - Acquisition (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
Note 2 - Acquisition (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Apr. 02, 2013
Business Combinations [Abstract]	'	'	'	'	'
Common stock issued to Aviva for all of their outstanding shares, shares	'	'	'	'	6,000,000
Common stock issued to Aviva for all of their outstanding shares, value	'	'	'	'	$6,000
Outstanding debts of Aviva assumed in acquisition	'	'	'	'	75,000
Accrued Interest on outstanding debts of Aviva assumed in acquisition	'	'	'	'	21,275
Impairment expense	$0	$0	($101,957)	($155,000)	'

Note_3_Intangible_Assets_Detai

Note 3 - Intangible Assets (Details Narrative) (USD $)	36 Months Ended
Note 3 - Intangible Assets (Details Narrative) (USD $)	Nov. 11, 2014	Nov. 11, 2012	Oct. 14, 2012	Jan. 27, 2012	Oct. 18, 2011	Oct. 17, 2011	Aug. 31, 2011
P3D Agreement	'	'	'	'	'	'	'
Minimum license agreement term (in years)	'	'	'	'	'	'	'21 years
Renewal term if not cancelled by either party 90 days in advance of expiration	'	'	'	'	'	'	'1 year
Minimum required cancellation notification required before expiration date to extend license a year	'	'	'	'	'	'	'90 days
Interest in outstanding common stock of IPR that P3D retained	'	'	'	'	'	9.90%	'
License Fee payment paid to IPR after receipt of bridge funding	'	'	'	'	$10,000	'	'
Simple interest rate on unpaid balance of license fee commencing on date of first $10,000 payment	'	'	'	'	'	'	6.00%
Gain from termination of agreement	'	'	96,347	'	'	'	'
Termination of note payable license fee amount	'	'	990,000	'	'	'	'
CPaiR Agreement	'	'	'	'	'	'	'
Minimum license agreement term (in years)	'	'21 years	'	'	'	'	'
Renewal term if not cancelled by either party 90 days in advance of expiration	'	'1 year	'	'	'	'	'
Minimum required cancellation notification required before expiration date to extend license a year	'	'90 days	'	'	'	'	'
Minimum payment to CPaiR to avoid termination	1,000,000	'	'	'	'	'	'
Period for which the license agreement must be paid in	'	'3 years	'	'	'	'	'
Royalties of sublease agreement paid percentage	'	20.00%	'	'	'	'	'
Payment of upfront license fee for CPaiR technology	'	20.00%	'	'	'	'	'
Percentage of gross revenues paid without subleasing	'	10.00%	'	'	'	'	'
Quarterly revenue paid to CPaiR	'	20.00%	'	'	'	'	'
ACSC Agreement	'	'	'	'	'	'	'
Upfront license fee paid to ACSC	'	'	'	$0	'	'	'
License agreement term (in years)	'	'	'	'1 year	'	'	'
Renewal term if not cancelled by either party 90 days in advance of expiration	'	'	'	'1 year	'	'	'
Percent of quarterly gross revenue owed by distributor or sub-licensee	'	'	'	25.00%	'	'	'
Gross revenue split ratio between IPR and ACSC	'	'	'	1	'	'	'
Percent of upfront license fee paid to ACSC	'	'	'	50.00%	'	'	'

Note_4_Notes_payable_Details

Note 4 - Notes payable (Details) (USD $)	12 Months Ended
Note 4 - Notes payable (Details) (USD $)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2013
Notes to Financial Statements	'	'	'	'	'	'
Future minimum payments due on notes	$158,000	$12,000	$12,000	$12,000	$524,000	'
Total future minimum payments due	'	'	'	'	'	$718,000

Note_4_Notes_payable_Details_N

Note 4 - Notes payable (Details Narrative) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

Oct. 31, 2013

Sep. 30, 2013

Jan. 31, 2013

Nov. 30, 2012

Oct. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 25, 2013

Aug. 30, 2013

10-May-13

Jan. 14, 2013

Jan. 31, 2013

Apr. 02, 2013

Promissory Note #1

Promissory Note #2

Promissory Note #3

Promissory Note Acquired By Aviva #1

Promissory Note Acquired By Aviva #2

IPR Private Placement

IPR Private placement maximum amount

$1,000,000

Notes payable issued in the private placement, minimum amount

25,000

Interest rate of notes payable issued in private placement

12.00%

Term of note payable issued in private placement

'1 year

Shares of common stock issued for each minimum amount loaned in private placement

102,850

Notes issued in IPR private placement

Aggregate principal amount of notes issued in IPR private placement

175,000

IPR notes oustanding

175,000

Common stock issued for private placement notes

719,950

Fair value of common stock issued for private placement notes

3,917

Noteholders agreeing to extend maturity date of notes

Term of extension of maturity date of notes

'1 year

Common stock issued for private placement note term extension

175,000

Fair value of common stock issed for private placement note term extension

175

Promissory notes issued

25,000

Balance on $25,000 October and November notes outstanding

50,000

Total outstanding notes payable excluding interest

225,000

Maturity of notes payable, amount

50,000

150,000

25,000

Financing amount on vehicle purchase, note payable

64,458

Interest rate of vehicle purchase financing

2.99%

Term of vehicle financing (in months)

'60 months

Monthly auto financing payment

1,060

Balance due on auto financing note

60,840

Aggregate principal amount of promissory note issued by the Company

10,000

25,000

100,000

Common shares issued for notes as a loan fee

50,000

125,000

500,000

Fair market value of common shares issued for notes as a note discount

125

25,000

75,000

Note interest rate per annum

10.00%

Maturity date of note

1-Jul-14

14-Apr-13

1-Jul-13

30-Jan-14

August 30 note matures upon completion of financing of certain amount

5,000,000

Note interest increase upon default

14.00%

Balance on $25,000 January 14 #1 note outstanding

25,000

Charge to interest expense upon issuance of #1 note

12,500

Interest paid on $25,000 January 14 #1 note outstanding

Balance on $25,000 January 14 #2 note outstanding

25,000

Charge to interest expense upon issuance of #2 note

12,500

Interest paid on $25,000 January 14 #2 note outstanding

Balance on $100,000 January 31 note outstanding

100,000

Interest paid on $100,000 January 31 note outstanding

Balance on $25,000 August 30 note outstanding

25,000

Balance on $10,000 September 25 note outstanding

10,000

Amortization of note discounts

103,566

Note discount unamortized

24,491

Notes Acquired in Acquisition of Aviva

Note acquired in acquisition, amount

25,000

50,000

Note acquired in acquisition, accrued interest

1,042

20,233

Note acquired in acquisition, percent interest

10.00%

Note acquired in acquisition, date of maturity

'2013-05-01

Balance of note acquired in acquisition, outstanding

25,000

50,000

Notes- Related Party

Aggregate principal amount of realted party promissory note issued by the Company

25,000

Common shares issued for related party notes as a loan fee

125,000

Related party note interest rate per annum

8.00%

Maturity date of related party note

'2013-10-10

Related party note discount

125

Balance of related party note outstanding

$16,988

Note_5_Shareholders_Deficit_De

Note 5 - Shareholders' Deficit (Details Narrative) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 21, 2013	Sep. 20, 2013	Feb. 22, 2013	Dec. 31, 2012
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 21, 2013	Sep. 20, 2013	Votes	Dec. 31, 2012
Common Stock	'	'	'	'	'	'	'
Revaluation of shares based on low trading volume	$0.00	'	'	'	'	'	'
Award grant shares	47,412,620	47,412,620	'	'	'	'	'
Award grant shares vested	27,657,197	27,657,197	'	'	'	'	'
Award grant shares unvested	19,755,423	19,755,423	'	'	'	'	'
Expense recorded for fair value of shares issued for services	'	$479,639	$178,897	'	'	'	'
Series AA Preferred Shares	'	'	'	'	'	'	'
Series AA Preferred stock, par value	$0.00	$0.00	'	'	'	$0.00	$0.00
Series AA Preferred stock, authorized	1,000,000	1,000,000	'	'	'	1,000,000	1,000,000
Series AA Preferred stock, outstanding	0	0	'	'	'	'	0
Number of votes for each preferred share	'	'	'	'	'	100,000	'
COMMON STOCK	'	'	'	'	'	'	'
Common stock, authorized	250,000,000	250,000,000	'	250,000,000	75,000,000	'	250,000,000

Note_6_Segment_Information_Det

Note 6 - Segment Information (Details Narrative) (USD $)	3 Months Ended		9 Months Ended
Note 6 - Segment Information (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Information	'	'	'	'
Net revenues of debt portfolio segment	$0	$7,161	$0	$16,926
Operating loss	-427,819	-372,640	-1,934,752	-1,193,842
Net Loss	-452,397	-392,899	-2,218,340	-1,409,290
Operating loss of intellectual property management segment	327,000	324,000	1,639,000	1,076,000
Operating loss of debt portfolio management segment	101,000	25,000	296,000	79,000
Operating loss of corporate overhead	'	$44,000	'	$254,000

Note_7_Fair_Value_Measurements3

Note 7 - Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Cash and cash equivalents	$1,208	$800	$3,098	$9,247
Fair Value Level 1	'	'	'	'
Cash and cash equivalents	1,208	800	'	'
Fair Value Level 2	'	'	'	'
Cash and cash equivalents	0	0	'	'
Fair Value Level 3	'	'	'	'
Cash and cash equivalents	0	0	'	'
Fair Value Total	'	'	'	'
Cash and cash equivalents	$1,208	$800	'	'

Note_8_Subsequent_Events_Detai

Note 8 - Subsequent Events (Details Narrative) (USD $)	Nov. 16, 2013	Oct. 01, 2013
Acquisition Agreement with WeHealAnimals, Inc.	'	'
Hanover common shares issued in Acquisition Agreement with WeHealAnimals, Inc.	300,000	'
Promissory note issued to WeHealAnimals, Inc. in Acquisition Agreement	$96,000	'
Percent of WeHealAnimals, Inc. acquired by Hanover in Acquisition Agreeement	100.00%	'
Series AA Super Voting Preferred Stock issued to CEO	'	1,000